Eli Lilly and Company (NYSE:LLY) is Capital Research Global Investors’ 10th Largest Position

Capital Research Global Investors grew its holdings in Eli Lilly and Company (NYSE:LLY) by 16.1% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 10,757,511 shares of the company’s stock after buying an additional 1,493,673 shares during the period. Eli Lilly and Company accounts for approximately 1.7% of Capital Research Global Investors’ portfolio, making the stock its 10th largest position. Capital Research Global Investors’ holdings in Eli Lilly and Company were worth $8,304,811,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Eli Lilly and Company by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 74,248,997 shares of the company’s stock worth $57,320,226,000 after purchasing an additional 475,530 shares during the period. Geode Capital Management LLC grew its stake in Eli Lilly and Company by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 17,382,846 shares of the company’s stock valued at $13,389,651,000 after acquiring an additional 291,875 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Eli Lilly and Company by 19.0% during the 4th quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company’s stock worth $9,747,214,000 after purchasing an additional 2,012,129 shares in the last quarter. Norges Bank purchased a new position in Eli Lilly and Company during the fourth quarter worth $8,407,908,000. Finally, Capital International Investors raised its stake in Eli Lilly and Company by 23.2% in the 4th quarter. Capital International Investors now owns 8,730,758 shares of the company’s stock valued at $6,740,272,000 after purchasing an additional 1,645,222 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

LLY has been the topic of several analyst reports. The Goldman Sachs Group upgraded Eli Lilly and Company from a “neutral” rating to a “buy” rating and decreased their price objective for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. Citigroup reduced their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Guggenheim decreased their price objective on shares of Eli Lilly and Company from $973.00 to $928.00 and set a “buy” rating for the company in a report on Monday, April 14th. Finally, Berenberg Bank set a $970.00 price target on Eli Lilly and Company in a research report on Thursday, January 16th. Two equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $1,012.00.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $841.70 on Friday. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The stock has a market cap of $798.08 billion, a price-to-earnings ratio of 71.88, a PEG ratio of 1.40 and a beta of 0.51. The stock’s 50 day moving average price is $829.09 and its 200 day moving average price is $820.35. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.